Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus (EBV)-derived peptide-HLA complexes represent a class of cell-surface antigens formed when intracellular EBV latent or lytic proteins are processed and presented by human leukocyte antigen (HLA) molecules. These complexes are crucial targets for the host immune system, particularly CD8+ and CD4+ T cells, which recognize them via T-cell receptors (TCRs) to initiate cytolytic clearance of infected cells. In EBV-associated malignancies—such as nasopharyngeal carcinoma, Hodgkin's lymphoma, Burkitt's lymphoma, gastric cancer, and post-transplant lymphoproliferative disease (PTLD)—tumor cells express specific EBV latent proteins (e.g., LMP1, LMP2, EBNA1, and the EBNA3 family) that are presented as peptide-HLA complexes. Therapeutic strategies targeting these complexes include TCR-engineered T-cell (TCR-T) therapies (such as YT-E001), TCR-like monoclonal antibodies (e.g., E1, L1, L2), bispecific antibodies, and peptide-selective chimeric antigen receptor (CAR) T cells (such as TÜ165). These agents mimic or utilize native TCR binding to selectively eliminate EBV-infected or malignant cells while sparing healthy tissue. However, clinical development is challenged by HLA restriction, potential cross-reactivity with self-peptides leading to off-tumor toxicity, and the immunosuppressive tumor microenvironment of solid tumors.
Redirection of cytotoxic T lymphocytes or engineered immune cells to recognize and lyse cells presenting EBV-derived peptides on HLA molecules, or direct antibody-mediated targeting via TCR-like antibodies to induce complement-dependent or antibody-dependent cellular cytotoxicity.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus-derived peptide-HLA complexes (EBV peptide-HLA complexes).